FDA approves infant combo vaccine for meningitis

(AP) — The first vaccine that protects children as young as six weeks against two potentially deadly bacterial infections has won approval from U.S. health regulators.

The Food and Drug Administration approved Menhibrix, a combination vaccine for infants and babies that prevents meningococcal disease and haemophilus influenza. Those bacteria can cause potentially deadly illness, or lead to blindness, mental retardation and amputation.

The FDA said the diseases are difficult to spot because their symptoms are similar to the common cold.

The vaccine is given in a four-dose regimen beginning as early as six weeks of age. The fourth dose can be given as late as 18 months of age.

The is manufactured by GlaxoSmithKline PLC at facilities in Belgium.


Explore further

Sanofi gets expanded meningitis vaccine approval

Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Citation: FDA approves infant combo vaccine for meningitis (2012, June 14) retrieved 28 November 2020 from https://medicalxpress.com/news/2012-06-fda-infant-combo-vaccine-meningitis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments